Best trending penny stocks to watch now? Check these 3 out for your watchlist The post Trending Penny Stocks to Buy Now? 3 Small-Caps to Watch...
TORONTO – In another step towards increasing digital access to mental health care, the Green Shield Canada group of companies is pleased to announce its...
When pharmaceutical Pfizer recently giant disclosed it was earmarking up to US$1 billion for its oral antiviral drug candidate (PF-07321332)—before knowing the Phase 2/3 blinded trial...
Highlights: Phase IIb COMP360 psilocybin therapy trial for treatment-resistant depression (TRD) close to completion; on track to report data by end of 2021 Partnership being developed...
90% Of Patients Treated With Experimental Israeli COVID Drug Discharged Within 5 Days Finally, it looks like the world might be on the verge of obtaining...
Would these vaccine stocks make for good investments amidst the current wave of coronavirus infections? The post Best Stocks To Buy Now? 4 Vaccine Stocks To...
OAKVILLE – Cardiol Therapeutics Inc. (TSX: CRDL), a clinical-stage biotechnology company focused on developing innovative anti-inflammatory therapies for the treatment of cardiovascular disease, announced today that...
Capricor Therapeutics in collaboration with the U.S. Army Institute of Surgical Research report a preclinical study on a rat model of acute traumatic coagulopathy (ATC) where...
For the first time in two years, Vertex has a COO. Stuart Arbuckle The cystic fibrosis drugmaker announced Wednesday that Stuart Arbuckle, who has led the...
Three pioneering technologies have forever altered how researchers do their work and promise to revolutionize medicine, from correcting genetic disorders to treating degenerative brain diseases.
The global anti-aging market is worth billions of dollars with significant growth potential. Here's a list of some of the anti-aging stocks looking to capitalize on...
Biotech penny stocks are heating up right now; here's 3 to watch The post Best Biotech Penny Stocks For Your Small-Caps Watchlist Right Now appeared first...
As more drugs are being approved, is FDA getting less advice than in the past? FDA maintains a vast network of outside advisors to provide input...
Are these penny stocks worth watching with the stock market down today? The post Top Penny Stocks to Buy? Why These 3 Should Be on Your...
Sage Therapeutics ended two late-stage studies of the depression drug zuranolone after discussions with the U.S. Food and Drug Administration led the company to believe they were unnecessary for...
In “Macbeth,” Shakespeare described sleep as the “chief nourisher in life’s feast.” But like his titular character, many adults aren’t sleeping well. Revery wants to help...
Gilead Sciences will open the doors to the company's new operations site in North Raleigh, N.C., as part of a business services center expansion. Gilead’s second-quarter 2021...
The U.S. Food and Drug Administration expanded the emergency use authorization of Regeneron Pharmaceuticals Inc.'s Covid-19 antibody cocktail, enabling the combo therapy's use as a preventive...
As one of the founding execs and longtime chief medical officer at Betta Pharma, Fenlai Tan isn’t just well aware of the allure of a me-better...
N-Dimethyltryptamine, or DMT, has experienced a recent surge in popularity in mental health and wellness communities. The naturally occurring psychedelic’s ties to shamanic practices and its...
Cell and gene therapies (C&GTs) present opportunities to not only treat disease, but to restore function and improve disease management. Although the opportunities with C&GTs are...
Editor’s note: Interested in following biopharma’s fast-paced IPO market? You can bookmark our IPO Tracker here. The biotech IPO rush continues, as three more companies — Nuvalent,...
The teams at Roche and Genentech are off and running at the FDA, with regulators accepting a quick pitch for what would be the first bispecific...
Officials at Cytiva and Pall, part of Danaher, will expand manufacturing capacity and services across geographies for global life sciences customers. A $1.5 billion two-year investment,...
The company's digital therapy platform works to measure and improve someone’s ability to walk after they have experienced a neurologic injury or disease.
What a difference a quarter can make. Stinging from a dip in sales for I/O blockbuster Opdivo last quarter, Bristol Myers Squibb’s top checkpoint inhibitor turned...
Boehringer Ingelheim’s latecomer antibody therapy for COVID-19 has been side-lined, as the company focuses its attention on its The post Boehringer takes alteplase to phase 3...
A week after it was reported that India’s Covid-19 death toll could be in the millions, antibody legend Tillman Gerngross has inked a deal to develop...
The U.S. Food and Drug Administration issued Incyte Corporation with a Complete Response Letter (CRL) over the company's Biologics License Application (BLA) for retifanlimab for anal cancer.
In PerkinElmer's largest purchase ever, the Massachusetts-based company is dropping a massive $5.25 billion in cash and stock to buy the biomedical research tool company BioLegend.